|
参考文献： [1] Fang W, Huang Y, Hong S, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer[J]. BMC Cancer, 2019, 19(1):595 [2] Xu CW, Wang WX, Wang D, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res. 2020;9(5):1853-1861. doi:10.21037/tlcr-20-382 [3] Zhao C, Jiang T, Li J, et al. The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. Transl Lung Cancer Res. 2020;9(4):1149-1158. doi:10.21037/tlcr-19-359 [4] Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5. Published 2019 Mar 8. doi:10.1038/s41392-019-0038-9 [5] 陈瑚,余英豪.EGFR基因20外显子突变与非小细胞肺癌[J].临床与实验病理学杂志,2014,(4):430-433,434.DOI:10.13315/j.cnki.cjcep.2014.04.019. [6] Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154-161. doi:10.1016/j.lungcan.2021.10.020 [7] Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179-184. doi:10.1097/JTO.0b013e3182779d18 [8] Chouaid C, et al. #9062-EGFR Exon 20 insertion prognostic and predictive values in advanced non-small cell lung cancer, a real world study[J]. J Clin Oncol. 2021;39(suppl 15). 截至2022年11月17日，Mobocertinib（莫博赛替尼）尚未获得中国国家药品监督管理局（NMPA）批准，以上信息仅供医疗卫生专业人士了解学术进展使用，武田公司不推荐说明书外应用。 |
|
|
